阿奇霉素联合头孢哌酮舒巴坦治疗小儿细菌性肺炎疗效观察

Observation on the efficacy of azithromycin combined with cefoperazone-sulbactam in the treatment of bacterial pneumonia in children

目的 观察阿奇霉素联合头孢哌酮舒巴坦治疗小儿细菌性肺炎的疗效。方法 48例小儿细菌性肺炎患儿,以随机数字表法分为对照组与研究组,各24例。对照组应用常规对症治疗,研究组应用阿奇霉素联合头孢哌酮舒巴坦治疗。比较两组疗效、临床症状消失时间、住院时间、炎症因子、免疫功能指标、不良反应发生情况。结果 研究组治疗总有效率为95.83%,高于对照组的75.00%,差异有统计学意义(P<0.05)。研究组喘息、肺部啰音、咳嗽、发热、哮鸣音消失时间及住院时间分别为(3.26±0.23)、(4.73±0.92)、(4.29±0.75)、(3.18±0.57)、(4.02±0.31)、(6.15±1.33)d,均短于对照组的(3.75±0.27)、(5.43±0.96)、(4.82±0.72)、(3.82±0.52)、(4.62±0.34)、(7.52±1.37)d,差异有统计学意义(P<0.05)。治疗后,研究组白细胞介素-6(IL-6)、超敏C反应蛋白(hs-CRP)、肿瘤坏死因子-α(TNF-α)分别为(241.32±23.34)pg/ml、(5.36±0.45)μg/ml、(89.21±10.07)ng/ml均低于对照组的(259.45±23.12)pg/ml、(5.75±0.41)μg/ml、(96.04±10.02)ng/ml,差异有统计学意义(P<0.05)。治疗后,研究组CD4+(36.04±4.35)%、CD8+(24.68±4.35)%、CD4+/CD8+(1.46±0.41)均优于对照组的(33.22±4.37)%、(27.91±4.42)%、(1.19±0.48),差异有统计学意义(P<0.05)。研究组不良反应发生率为4.17%,低于对照组的25.00%,差异有统计学意义(P<0.05)。结论 给予小儿细菌性肺炎患儿阿奇霉素联合头孢哌酮舒巴坦治疗效果确切,可明显改善疾病症状与免疫功能,还可抑制炎症因子水平,减少药物不良反应,具有理想的临床应用价值。

Objective To observe the efficacy of azithromycin combined with cefoperazone-sulbactam in the treatment of bacterial pneumonia in children.Methods A total of 48 children with bacterial pneumonia were randomly divided into the control group and the research group,with 24 cases in each group.The control group was treated with conventional symptomatic treatment,while the research group was treated with azithromycin combined with cefoperazone-sulbactam.The clinical efficacy,disappearance time of clinical symptoms,hospitalization time,inflammatory factors,immune function indicators,and occurrence of adverse reactions of the two groups were compared.Results The total effective rate of the research group was 95.83%,which was higher than 75.00%of the control group,and the difference was statistically significant (P<0.05).The disappearance time of pant,lung rale,cough,fever,wheezing,and hospitalization time in the research group were (3.26±0.23),(4.73±0.92),(4.29±0.75),(3.18±0.57),(4.02±0.31),and (6.15±1.33) d,which were shorter than (3.75±0.27),(5.43±0.96),(4.82±0.72),(3.82±0.52),(4.62±0.34),and (7.52±1.37) d in the control group,and the differences were statistically significant (P<0.05).After treatment,the research group had interleukin-6 (IL-6) of (241.32±23.34) pg/ml,high-sensitivity C-reactive protein (hs-CRP) of (5.36±0.45)μg/ml,and tumor necrosis factor-α(TNF-α) of (89.21±10.07) ng/ml,which were lower than (259.45±23.12) pg/ml,(5.75±0.41)μg/ml,and(96.04±10.02) ng/ml in the control group,and the differences were statistically significant (P<0.05).After treatment,the research group had CD4+of (36.04±4.35)%,CD8+of (24.68±4.35)%,and CD4+/CD8+of(1.46±0.41),which were better than (33.22±4.37)%,(27.91±4.42)%,and (1.19±0.48) in the control group,and the differences were statistically significant (P<0.05).The incidence of adverse reactions in the research group was4.17%,which was lower than 25.00%in the control group,and the difference was statistically significant (P<0.05).Conclusion Azithromycin combined with cefoperazone sulbactam has a definite therapeutic effect on children with bacterial pneumonia.It can significantly improve disease symptoms and immune function,inhibit the level of inflammatory factors,reduce adverse drug reactions,and has ideal clinical application value.